- Home
- TARA vs CGTX Comparison
TARA vs CGTX Comparison
Compare TARA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- CGTX
- Stock Information
- Founded
- TARA N/A
- CGTX 2007
- Country
- TARA United States
- CGTX United States
- Employees
- TARA N/A
- CGTX N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- CGTX Health Care
- Exchange
- TARA Nasdaq
- CGTX Nasdaq
- Market Cap
- TARA 196.8M
- CGTX 158.8M
- IPO Year
- TARA N/A
- CGTX 2021
- Fundamental
- Price
- TARA $5.20
- CGTX $1.58
- Analyst Decision
- TARA Strong Buy
- CGTX Strong Buy
- Analyst Count
- TARA 6
- CGTX 3
- Target Price
- TARA $19.80
- CGTX $2.83
- AVG Volume (30 Days)
- TARA 504.0K
- CGTX 1.9M
- Earning Date
- TARA 11-03-2025
- CGTX 11-12-2025
- Dividend Yield
- TARA N/A
- CGTX N/A
- EPS Growth
- TARA N/A
- CGTX N/A
- EPS
- TARA N/A
- CGTX N/A
- Revenue
- TARA N/A
- CGTX N/A
- Revenue This Year
- TARA N/A
- CGTX N/A
- Revenue Next Year
- TARA N/A
- CGTX N/A
- P/E Ratio
- TARA N/A
- CGTX N/A
- Revenue Growth
- TARA N/A
- CGTX N/A
- 52 Week Low
- TARA $2.21
- CGTX $0.22
- 52 Week High
- TARA $10.48
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- TARA 57.60
- CGTX 45.58
- Support Level
- TARA $4.96
- CGTX $1.57
- Resistance Level
- TARA $5.32
- CGTX $1.78
- Average True Range (ATR)
- TARA 0.30
- CGTX 0.14
- MACD
- TARA -0.11
- CGTX -0.02
- Stochastic Oscillator
- TARA 15.55
- CGTX 4.17
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.